Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Amy D. Klion, Jamie Robyn, Cem Akin, Pierre Noel, Margaret Brown, Melissa Law, Dean D. Metcalfe, Cynthia Dunbar, Thomas B. Nutman

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

We recently described a subset of patients with a myeloproliferative variant of hypereosinophilic syndrome (MHES) characterized by elevated serum tryptase levels, increased atypical mast cells in the bone marrow, tissue fibrosis, and the presence of the fusion tyrosine kinase, FIP1L1-PDGFRα, which is a therapeutic target of imatinib mesylate. Seven patients with MHES were treated with imatinib mesylate (300-400 mg daily). Clinical improvement and resolution of eosinophilia was observed in all patients, although cardiac dysfunction, when present, was not altered by therapy. Reversal of bone marrow pathology, including increased cellularity, the presence of spindle-shaped mast cells, and myelofibrosis, was evident in all patients at 4 to 8 weeks following initiation of therapy. This was accompanied by a decrease in activated eosinophils and mast cells in the peripheral blood and bone marrow, respectively. Serum tryptase levels declined rapidly to normal levels in all patients and remained in the normal range throughout therapy. Molecular remission, with disappearance of detectable FIP1L1/PDGFRA (F/P) transcripts, was achieved in 5 of 6 patients tested. The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES.

Original languageEnglish (US)
Pages (from-to)473-478
Number of pages6
JournalBlood
Volume103
Issue number2
DOIs
StatePublished - Jan 15 2004
Externally publishedYes

Fingerprint

Hypereosinophilic Syndrome
Primary Myelofibrosis
Tryptases
Bone
Mast Cells
Pathology
Protein-Tyrosine Kinases
Blood
Fusion reactions
Therapeutics
Tissue
Bone Marrow
Imatinib Mesylate
Eosinophilia
Serum
Eosinophils
Reference Values
Bone and Bones
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. / Klion, Amy D.; Robyn, Jamie; Akin, Cem; Noel, Pierre; Brown, Margaret; Law, Melissa; Metcalfe, Dean D.; Dunbar, Cynthia; Nutman, Thomas B.

In: Blood, Vol. 103, No. 2, 15.01.2004, p. 473-478.

Research output: Contribution to journalArticle

Klion, Amy D. ; Robyn, Jamie ; Akin, Cem ; Noel, Pierre ; Brown, Margaret ; Law, Melissa ; Metcalfe, Dean D. ; Dunbar, Cynthia ; Nutman, Thomas B. / Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. In: Blood. 2004 ; Vol. 103, No. 2. pp. 473-478.
@article{15b5201931b142508ba74f2d52e12134,
title = "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome",
abstract = "We recently described a subset of patients with a myeloproliferative variant of hypereosinophilic syndrome (MHES) characterized by elevated serum tryptase levels, increased atypical mast cells in the bone marrow, tissue fibrosis, and the presence of the fusion tyrosine kinase, FIP1L1-PDGFRα, which is a therapeutic target of imatinib mesylate. Seven patients with MHES were treated with imatinib mesylate (300-400 mg daily). Clinical improvement and resolution of eosinophilia was observed in all patients, although cardiac dysfunction, when present, was not altered by therapy. Reversal of bone marrow pathology, including increased cellularity, the presence of spindle-shaped mast cells, and myelofibrosis, was evident in all patients at 4 to 8 weeks following initiation of therapy. This was accompanied by a decrease in activated eosinophils and mast cells in the peripheral blood and bone marrow, respectively. Serum tryptase levels declined rapidly to normal levels in all patients and remained in the normal range throughout therapy. Molecular remission, with disappearance of detectable FIP1L1/PDGFRA (F/P) transcripts, was achieved in 5 of 6 patients tested. The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES.",
author = "Klion, {Amy D.} and Jamie Robyn and Cem Akin and Pierre Noel and Margaret Brown and Melissa Law and Metcalfe, {Dean D.} and Cynthia Dunbar and Nutman, {Thomas B.}",
year = "2004",
month = "1",
day = "15",
doi = "10.1182/blood-2003-08-2798",
language = "English (US)",
volume = "103",
pages = "473--478",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

AU - Klion, Amy D.

AU - Robyn, Jamie

AU - Akin, Cem

AU - Noel, Pierre

AU - Brown, Margaret

AU - Law, Melissa

AU - Metcalfe, Dean D.

AU - Dunbar, Cynthia

AU - Nutman, Thomas B.

PY - 2004/1/15

Y1 - 2004/1/15

N2 - We recently described a subset of patients with a myeloproliferative variant of hypereosinophilic syndrome (MHES) characterized by elevated serum tryptase levels, increased atypical mast cells in the bone marrow, tissue fibrosis, and the presence of the fusion tyrosine kinase, FIP1L1-PDGFRα, which is a therapeutic target of imatinib mesylate. Seven patients with MHES were treated with imatinib mesylate (300-400 mg daily). Clinical improvement and resolution of eosinophilia was observed in all patients, although cardiac dysfunction, when present, was not altered by therapy. Reversal of bone marrow pathology, including increased cellularity, the presence of spindle-shaped mast cells, and myelofibrosis, was evident in all patients at 4 to 8 weeks following initiation of therapy. This was accompanied by a decrease in activated eosinophils and mast cells in the peripheral blood and bone marrow, respectively. Serum tryptase levels declined rapidly to normal levels in all patients and remained in the normal range throughout therapy. Molecular remission, with disappearance of detectable FIP1L1/PDGFRA (F/P) transcripts, was achieved in 5 of 6 patients tested. The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES.

AB - We recently described a subset of patients with a myeloproliferative variant of hypereosinophilic syndrome (MHES) characterized by elevated serum tryptase levels, increased atypical mast cells in the bone marrow, tissue fibrosis, and the presence of the fusion tyrosine kinase, FIP1L1-PDGFRα, which is a therapeutic target of imatinib mesylate. Seven patients with MHES were treated with imatinib mesylate (300-400 mg daily). Clinical improvement and resolution of eosinophilia was observed in all patients, although cardiac dysfunction, when present, was not altered by therapy. Reversal of bone marrow pathology, including increased cellularity, the presence of spindle-shaped mast cells, and myelofibrosis, was evident in all patients at 4 to 8 weeks following initiation of therapy. This was accompanied by a decrease in activated eosinophils and mast cells in the peripheral blood and bone marrow, respectively. Serum tryptase levels declined rapidly to normal levels in all patients and remained in the normal range throughout therapy. Molecular remission, with disappearance of detectable FIP1L1/PDGFRA (F/P) transcripts, was achieved in 5 of 6 patients tested. The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES.

UR - http://www.scopus.com/inward/record.url?scp=0942276859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942276859&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-08-2798

DO - 10.1182/blood-2003-08-2798

M3 - Article

VL - 103

SP - 473

EP - 478

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -